Horizon Pharma plc Announces the U.S. Patent and Trademark

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid

DUBLIN, Ireland, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ: HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 13/610,580, entitled "Methods of Therapeutic Monitoring of Phenylacetic Acid Prodrugs" that covers Horizon's U.S. approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid.

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed.  The U.S. patent scheduled to issue from this application will expire on September 22, 2030.  After issuance, Horizon plans to list the U.S. patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.

About RAVICTI® RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients ≥2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline and protein-free calorie supplements).  RAVICTI is indicated for use in all 28 Member States of the European Union and 3 Member States of the European Economic Area as a nitrogen-binding agent for chronic management of adult and pediatric patients two months of age and older with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  RAVICTI is indicated for use in Canada as an adjunctive therapy for chronic management of adult and pediatric patients two years of age and older with UCDs. 

Important Safety Information

LIMITATIONS OF USE:

  • RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels
  • The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established
  • The use of RAVICTI in patients <2 months of age is contraindicated

CONTRAINDICATIONS:

  • In patients less than 2 months of age
  • In patients who develop or have known hypersensitivity to phenylbutyrate

WARNINGS AND PRECAUTIONS:

  • Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels ≥500 µg/mL.  Reduce RAVICTI dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses.
  • Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia.  Monitor ammonia levels closely.
  • RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data it may cause fetal harm.  A voluntary patient registry will include evaluation of pregnancy outcomes in patients with UCDs. For more information regarding the registry program, visit  www.ucdregistry.com  or call 1-855-823-2592.
  • Caution should be exercised when administering RAVICTI to nursing mothers, as breastfeeding is not recommended with maternal use of RAVICTI.  It is not known whether RAVICTI or its metabolites are present in breast milk.

ADVERSE REACTIONS:

  • Adverse reactions occurring in ≥10% of adult patients during short-term treatment (n=44, 4 weeks) with RAVICTI were diarrhea, flatulence, and headache.
  • Adverse reactions occurring in ≥10% of adult patients during long-term treatment (n=51, 12 months) with RAVICTI were nausea, vomiting, diarrhea, decreased appetite, hyperammonemia, dizziness, headache, and fatigue.
  • Adverse events occurring in ≥10% of pediatric patients during long-term treatment (n=26, 12 months) with RAVICTI were upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, hyperammonemia, and headache.

DRUG INTERACTIONS:

  • Corticosteroids, valproic acid, or haloperidol:  May increase plasma ammonia level. Monitor ammonia levels closely.
  • Probenecid:  May affect renal excretion of metabolites of RAVICTI, including PAGN and PAA.

About Urea Cycle Disorders (UCDs) Urea Cycle Disorders or UCDs are inherited metabolic diseases caused by a deficiency of one of the enzymes or transporters that constitute the urea cycle.  The urea cycle involves a series of biochemical steps in which ammonia, a potent neurotoxin, is converted to urea, which is excreted in the urine.  UCD patients may experience episodes where they get symptoms from the ammonia in their blood being excessively high – called hyperammonemic crises – which may result in irreversible brain damage, coma or death.  UCD symptoms may first occur at any age depending on the severity of the disorder, with more severe defects presenting earlier in life.

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com .  Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the issuance of a patent based on the Notice of Allowance from the U.S. Patent and Trademark Office, the expected term of the patent, if issued, potential patent protection for RAVICTI and plans to list newly issued patents in the FDA's Orange Book.  These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors.  These factors include risks regarding whether the administrative processes required for the issuance of a patent as indicated in the Notice of Allowance will be completed in a timely matter or at all, whether the patent, if issued as indicated in the Notice of Allowance, will provide sufficient protection and market exclusivity for RAVICTI, whether any patents covering RAVICTI may be challenged, invalidated, infringed or circumvented by third parties and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings.  Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts: Investors: Tina Ventura Senior Vice President, Investor Relations investor-relations@horizonpharma.com U.S. Media: Geoff Curtis Senior Vice President, Corporate Communications media@horizonpharma.com Ireland Media: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 199

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Swell Partners' Awards Highlight Culture, Not Metrics

Updated Category News Views 26

Recognition Lands in a Crowded Talent Market Two shiny Stevie trophies do not pay payroll, but they can say something useful about a company trying to stand out in the noisy talent-services business. Swell Partners has been named 2026 Company of the Year in Business Services and has seen founder and CEO Cari Gatto receive Best Female CEO of the Year. For a private firm...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 118

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 68

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 21

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 88

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Hagerty's Fifth Film Win Keeps Its Media Engine Humming

Updated Category News Views 57

A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...

Continue Reading
Housing's Value Equation Is Getting More Complicated

Updated Category News Views 82

A homeowner's insurance bill has become a louder market signal than a granite countertop. Green Builder Media's latest batch of research, publishing and events is aimed squarely at that uncomfortable truth: housing is no longer judged only by the price on the contract. Buyers, builders, lenders and insurers are being pushed to reckon with what a home costs to own, protect...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 61

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 50

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading

Top 5 Most Recently Viewed Articles

Private Tutoring Insights: Learning from Finland's Education Method

Updated Category News Views 206

Exploring Finland's Educational Principles for Private Tutoring In today's rapidly evolving educational landscape, Tutors International passionately investigates various global education models. One system that stands out is Finland's renowned educational approach, widely admired for its emphasis on holistic learning and well-being. Tutors International's latest analysis...

Continue Reading
Charter Communications and Cox Communications Join Forces

Updated Category News Views 162

Charter Communications Merges with Cox Communications In a pivotal move for the telecommunications industry, Charter Communications and Cox Communications have entered into a definitive agreement to combine their companies. This merger signifies a significant consolidation within the sector, promising advancements in service delivery and enhanced operational efficiency...

Continue Reading
Investor Insights on Dyne Therapeutics: Understanding Risks

Updated Category News Views 568

Understanding the Current Situation of Dyne Therapeutics Dyne Therapeutics, Inc. (NASDAQ: DYN) is currently under scrutiny as Pomerantz LLP investigates potential claims on behalf of investors. The concerns arise regarding whether Dyne and its executives may have engaged in improper securities practices. Investors holding shares or contemplating an entry into the market...

Continue Reading
Scientology's New Campaign Aims to Inspire Global Engagement

Updated Category News Views 116

Scientology Launches Global Welcome Campaign The Church of Scientology International is excited to unveil its innovative Global Welcome to Scientology campaign. This initiative is a powerful effort focused on bringing people together and elevating the human experience through understanding and discovery. Inspiring Discovery Across the Globe With the aim of fostering a...

Continue Reading
Deborah R. Willig Shines in Lawdragon's Prestigious Award List

Updated Category News Views 241

Deborah R. Willig Recognized Among Leading Civil Rights Attorneys Willig, Williams & Davidson proudly announces that Deborah R. Willig, the firm's managing partner, has once again earned a spot in the esteemed Lawdragon 500 list of leading civil rights and plaintiff employment lawyers. This recognition underscores her unwavering commitment to advocating for workers'...

Continue Reading